Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Clasificación en acciones #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Precio por acción
$0.07339369
Última sincronización: 2026-08-18
Capitalización bursátil
$25.24M
Cambio (1 día)
5.26%
Cambio (1 año)
-9.55%
País
CA
Comercio Resverlogix Corp. (RVX)

Categoría

Ratio P/B de Resverlogix Corp. (RVX)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Resverlogix Corp., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Resverlogix Corp. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH